Abstract: Described are techniques for corroborating anomalous behavior. The techniques include training devices included in an Internet of Things (IoT) mesh network to independently identify occurrences of anomalous behavior in a proximate physical environment. The techniques further include receiving event data from at least a portion of the devices in the IoT mesh network corresponding to a time window, where the event data reports occurrences of at least one type of anomalous behavior. The techniques further include corroborating the at least one type of anomalous behavior to determine that the occurrences of the at least one type of anomalous behavior indicate an anomalous event that meets a reporting threshold for providing notice of the anomalous event. The techniques further include generating a notification regarding the anomalous event.

Abstract: Provided herein are compositions, and methods for administering a platelet derivative composition for reducing bleeding in a subject who is refractory to platelet transfusion. Methods herein can further include administering a platelet derivative composition to a subject having low platelet counts (e.g., having thrombocytopenia) and/or to maintain the number of platelets over a threshold amount, or to increase the number of platelets in the subject. Methods herein can include administering a therapeutic agent before and optionally after administering the platelet derivative composition to the subject. Methods herein can reduce or eliminate any dosing and/or scheduling adjustments of a therapeutic regimen due to a low platelet count.

Abstract: Provided herein are methods for administering platelet derivatives, such as freeze-dried platelet derivatives (FDPDs) to a subject having Hermansky Pudlak Syndrome (HPS) or Bernard Soulier Syndrome (BSS), comprising administering an effective dose of the platelet derivatives in a platelet derivative composition to the subject. The platelet derivatives can have numerous characteristics provided herein, that make them well suited to restore hemostatic functions in the subject. In some embodiments, the platelet derivatives are from a pool of donors. Furthermore, provided herein are platelet derivatives, and methods using the same, that have numerous beneficial properties, as provided.

Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

Abstract: The disclosed methods, systems, and kits provide the ability to deliver entire clean sheet designs from concept to first hot fire in under six weeks with instant specific impulses above 330 seconds in some of our engines. In examples, thrusters can be delivered that are at less than half of the mass budget allowable for them and they can be delivered in weeks.

Abstract: A system that detects when a user starts an action, such as a golf stroke or tennis stroke, and provides feedback to indicate the desired timing of one or more phases of the action. For example, timing feedback signals may be sent to indicate when each phase should ideally finish as a training aid to guide the user towards improving performance of the action. Equipment used by the user may be equipped with an inertial motion sensor that captures data throughout the action; data may be transmitted to a processor, such as a mobile device or a server, for analysis, and feedback signals (such as audio tones) may be sent to the user throughout the action based on this analysis. The user may initiate an action at any time, without needing a prompt from the system to begin the action, since the system may dynamically detect when an action begins.

Abstract: Provided herein are methods for administering platelet derivatives, such as freeze-dried platelet derivatives (FDPDs) to a subject, comprising administering an effective dose of the platelet derivatives in a platelet derivative composition to the subject. Such effective dose in illustrative embodiments, includes multiple individual doses, or a continuous dose administered within a time period, for example a time period of less than 4 hours. In certain aspects herein the subject is a subject having Hermansky Pudlak Syndrome (HPS). The platelet derivatives can have numerous characteristics provided herein that make them well suited to restore hemostatic functions in the subject. In some embodiments, the platelet derivatives are from a pool of donors, and are HLA Class 1-characterized platelet derivatives (e.g., FDPDs), which in certain illustrative embodiments are HLA Class 1-matched FDPDs.

Abstract: An adjustable medical/veterinary suture crimp tool includes a stationary jaw at a distal end of fixed shank, a moveable jaw at a distal end of a linearly driven crossbar for deforming a crimp tube located between the stationary jaw and the moveable jaw, a first handle connected to a fixed shank, and a second handle pivotably connected to the fixed shank and configured to drive the crossbar linearly with respect to the fixed shank to crimp the crimp tube. A stop is configured to limit the extent of travel of the crossbar and a mechanism, cooperating with the stop, adjusts the extent of travel of the crossbar to vary the level of crimp tube deformation.

Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

Abstract: A financial institution computing system includes an account database with a plurality of transaction parameters with respect to a financial account of a customer, a receptiveness metrics circuit structured to extract the plurality of transaction parameters from the account database, the transaction parameters including at least one financial transaction record, and indicative of a mode of the customer, and determine one or more receptiveness metrics attributed to the customer based on the mode of the customer, the one or more receptiveness metrics indicating likelihoods of the customer converting an interaction from the financial institution, wherein the interaction includes an avatar that is an aged version of the customer, and an interaction generation circuit structured to transmit the interaction to the customer at an optimal time based on the one or more receptiveness metrics.

Abstract: The present invention relates to the discovery of novel N-(substituted)-1H-1,2,4-triazole-3-carboxamide compounds capable of inhibiting DksA activity in a bacteria cell. In certain embodiments, the compounds are capable of killing or weakening bacteria. In another aspect, the invention relates to methods of treating bacterial infection in a subject in need thereof, the method comprising administering to the subject a compound of the invention.

Abstract: A financial institution computing system includes an account database with a plurality of transaction parameters with respect to a financial account of a customer, a receptiveness metrics circuit structured to extract the plurality of transaction parameters from the account database, the transaction parameters including at least one financial transaction record, and indicative of a mode of the customer, and determine one or more receptiveness metrics attributed to the customer based on the mode of the customer, the one or more receptiveness metrics indicating likelihoods of the customer converting an interaction from the financial institution, wherein the interaction includes an avatar that is an aged version of the customer, and an interaction generation circuit structured to transmit the interaction to the customer at an optimal time based on the one or more receptiveness metrics.

Abstract: The invention provides methods of inhibiting the growth or metastasis of a cancer in a mammal by inhibiting a Ral GTPase in the mammal. The invention also provides small molecule inhibitors of Ral GTPases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds of the invention, and methods of using the same.

Abstract: A system that analyzes motion of a putter and provides feedback to the golfer as a training aid to guide the golfer towards making better putting strokes. The putter may be equipped with an inertial motion sensor that captures data throughout a stroke; data may be transmitted to a processor, such as a mobile device or a server, for analysis, and feedback signals may be sent to the golfer throughout the stroke based on this analysis. For example, audio tones (generated for example by a mobile phone) may change depending on whether the putting stroke has the desired characteristics. The system may support different operating modes that provide feedback on different putting features. Illustrative modes may for example provide feedback on the putter orientation at address, on the timing of the backstroke, and on the changes in putter face orientation through the stroke.

Abstract: Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.

Abstract: Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.

Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

Abstract: Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.

Abstract: Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.

Abstract: In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.